CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+/- 14 days).

  * Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
* Age ≤ 30 years at CAR T cell infusion.

Exclusion Criteria:

* Active malignancy other than the disease under study.
* Planned consolidative HSCT within 3 months post CAR T cell infusion.
* Received or planned additional disease directed therapy post CAR T cell infusion.
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

主要终点：Presence of bone marrow dysfunction (BMD) · Among patients in remission or without bone marrow involvement of disease in the B-ALL cohort, we will summarize the rates of prevalent BMD at 3- and 6-months post-infusion and estimate the cumulative incidence of new BMD and BMD recovery for patients with prevalent BMD at 3- and 6-months. · Within 6 months post CAR T-cell therapy；Occurrence of clinically significant infections · The infection density of clinically significant infections in 3-6 months will be summarized in the B-ALL cohort. · Within 6 months post CAR T-cell therapy；Presence of persistent ICANS · We will summarize the rates of persistent ICANS at 3- and 6-months post-infusion and estimate the cumulative incidence and timing of new ICANS and ICANS recovery for patients with persistent ICANS at 3- and 6-months in the B-ALL cohort. · Within 6 months post CAR T-cell therapy
次要终点：Presence of bone marrow dysfunction (BMD)；Severity of BMD；Occurrence of clinically significant infections；Time to the earliest clinically significant infection；Severity of clinically significant infections；Presence of persistent ICANS；Severity of persistent ICANS

• B cell acute lymphoblastic leukemia (B cell acute lymphoblastic leukemia (B-ALL) ) cohort · B-ALL participants who have received initial CAR T cell therapy within the last 1-3 months.
• Other hematologic malignancy · Other hematologic malignancy participants who have received initial CAR T cell therapy within the last 1-3 months.
• Solid tumor (ST) · ST participants who have received initial CAR T cell therapy within the last 1-3 months.

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.